Ranbaxy Wants Equal Trial Time In 'Bet The Company' MDL

By Brian Dowling (January 14, 2022, 1:05 PM EST) -- Ranbaxy Inc. is urging a Boston federal judge to give it equal time to defend itself in an upcoming "bet the company" trial with tens of billions of dollars potentially at stake on claims it manipulated the drug approval process to block competitors from making generic versions of three drugs.

Thursday's filing came one day after U.S. District Judge Nathaniel M. Gorton drew up strict time limits for the April 5 trial in the multidistrict case, allocating 36 hours for the plaintiffs and 27 hours for Ranbaxy and its parent company, Sun Pharmaceuticals Inc.

The plaintiffs — direct purchasers such as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!